研究者詳細 - 上山　純

論文 - 上山　純

分割表示 131 件中 61 - 80 件目／全件表示 >>

A non-invasive biomonitoring method for assessing levels of urinary pyrethroid metabolites in diapered children by gas chromatography-mass spectrometry. 査読有り

SAITO Shun, UEYAMA Jun, KONDO Takaaki, SAITO Isao, SHIBATA Eiji, GOTOH Masahiro, NOMURA Hiroshi, WAKUSAWA Shinya, NAKAI Kunihiko, KAMIJIMA Michihiro.

J Expo Sci Environ Epidemiol 24 巻 ( 2 ) 頁： 200-7 2014年3月

A revised method for determination of serum mercaptalbumin and nonmercaptalbumin by high performance liquid chromatography coupled with post-column bromocresol green reaction. 査読有り

UEYAMA Jun, ISHIKAWA Yusuke, KONDO Takaaki, MOTOYAMA Megumi, MATSUMOTO Hiroyuki, MATSUSHITA Tadashi

Ann Clin Biochem. in press 巻頁： in press 2014年3月

Biochemical staging of the chronic hepatic lesions of Wilson disease. 査読有り

Katano Y, Hayashi K, Hattori A, Tatsumi Y, Ueyama J, Wakusawa S, Yano M, Toyoda H, Kumada T, Mizutani N, Hayashi H, Goto H.

Nagoya J Med Sci. 76 巻 ( 1-2 ) 頁： 139-148 2014年2月

Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells. 査読有り

Komori Y, Arisawa S, Takai M, Yokoyama K, Honda M, Hayashi K, Ishigami M, Katano Y, Goto H, Ueyama J, Ishikawa T, Wakusawa S.

Eur J Pharmacol. 724 巻頁： 161-167 2014年2月

Quantitation of neonicotinoid metabolites in human urine using GC-MS. 査読有り

NOMURA Hiroshi, UEYAMA Jun, KONDO Takaaki, SAITO Isao, MURATA Katsuyuki, IWATA Toyoto, WAKUSAWA Shinya, KAMIJIMA Michihiro

Journal of Chromatography B 941 巻頁： 109-115 2013年12月

Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats. 査読有り

ARAKAWA-TODO Mika, UEYAMA Jun, NOMURA Hiroshi, ABE Fumie, TSUKIYAMA Ikuto, MATSUURA Katsuhiko, HASEGAWA Takaaki

Anticancer Research 33 巻 ( 8 ) 頁： 3089-3097 2013年8月

Preparation of dealcholized onetaxotere®, docetaxel injection formulation and its pharmacokinetics in rats. 査読有り

Onishi Katsuhiro, TSUKIYAMA Ikuto, UEYAMA Jun, ABE Fumie, SAITO Hiroko, MATSUURA Katsuhiko, NADAI Masayuki, HASEGAWA Takaaki

Gan To Kagaku Ryoho. 40 巻 ( 7 ) 頁： 891-986 2013年7月

Various copper and iron overload patterns in the livers of patients with Wilson disease and idiopathic copper toxicosis 査読有り

HAYASHI Hisao, HATTORI Ai, TATSUMI Yasuaki, HAYASHI Kazuhiko, KATANO Yoshiaki, UEYAMA Jun, WAKUSAWA Shinya, YANO Motoyoshi, GOTO Hidemi

Med Mol Morphol. 22 巻頁： 00-00 2013年1月

Evidence for diazinon-mediated inhibition of cis-permethrin metabolism and its effects on reproductive toxicity in adult male mice 査読有り

WANG Dong, KAMIJIMA Michihiro, OKAMURA Ai, ITO Yuki, YANAGIBA Yukie, JIA Xiao-fang, NAITO Hisao, UEYAMA Jun, NAKAJIMA Tamie

Reprod Toxicol. 34 巻頁： 489-497 2012年12月

Urinary concentrations of organophosphorus insecticide metabolites in Japanese workers 査読有り

UEYAMA Jun, SAITO Isao, KONDO Takaaki, TAKI Tomoko, KIMATA Akiko, SAITO Shun, ITO Yuki, MURATA Katsuyuki, IWATA Toyoto, GOTOH Masahiro, SHIBATA Eiji, WAKUSAWA Shinya, KAMIJIMA Michihiro

Chemosphere 87 巻頁： 1403-1409 2012年6月

Prevalence of Helicobacter Pylori Infection Measured with Urinary Antibody in an Urban Area of Japan, 2008-2010 査読有り

TAMURA Takashi, MORITA Emi, KONDO Takaaki, UEYAMA Jun, TANAKA Tetsuya, KIDA Yuto, HORI Yoko, INOUE Shigeru, TOMITA Koutaro, OKADA Rieko, KAWAI Sayo, HISHIDA Asahi, NAITO Mariko, WAKAI Kenji and HAMAJIMA Nobuyuki

Nagoya Journal of Medical Science 74 巻頁： 63-70 2012年2月

New analytical method for sensitive quantification of urinary 3-methyl-4-nitrophenol to assess fenitrothion exposure in general population and occupational sprayers 査読有り

OKAMURA Ai, SAITO Isao, UEYAMA Jun, ITO Yuki, NAKAJIMA Tamie, KAMIJIMA Michihiro

Toxicol Lett. 210 巻 ( 2 ) 頁： 220-224 2011年11月

Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats 査読有り

KATO Ayako, UEYAMA Jun, ABE Fumie, HOTTA Kazuo, TSUKIYAMA Ikuo, OSHIMA Taeyuki, KONDO F, SAITO Hiroko, HASEGAWA Takaaki.

Anticancer Res. 31 巻 ( 9 ) 頁： 2915-2922 2011年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

PubMed ID21868538
The present study has investigated the effect of panipenem, a widely used antibiotic, on the pharmacokinetics of an active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxy-camptothecin (SN-38) and SN-38 glucuronide (SN-38G) produced by uridine-diphosphate glucuronosyltransferase (UGT) 1A isoform-mediated glucuronidation in rats. Rats received a 1 h infusion with panipenem at a loading dose of 10 mg/kg and a maintenance dose of 15 mg/min/kg once a day for 5 days. When the effect of pretreatment with panipenem on glucuronidation activities of substrates for hepatic UGT1A isoforms was investigated using substrates 4-methylumbelliferone (4MU), estradiol and SN-38, the rate of 4MU glucuronide formation was significantly increased, but that of estradiol glucuronide formation was unchanged. However, the rate of SN-38G formation showed a tendency to increase. One hour after the final infusion of panipenem or saline, SN-38 (2 mg/kg) was administered intravenously in rats with or without bile duct cannulation. Pretreatment with panipenem had no effect on the plasma concentration-time curves and biliary excretion of SN-38 and SN-38G in rats with and without bile duct cannulation. There were also no significant differences in the relative extent of glucuronidation of SN-38 to SN-38G (AUC(2 h, SN-38G)/AUC(2 h, SN-38)) between panipenem-treated and untreated rats. These findings suggest that pretreatment with panipenem does not alter the pharmacokinetics of SN-38 and SN-38G, suggesting the possibility that panipenem can be used safely for cancer patients undergoing irinotecan chemotherapy.

Study Profile on Baseline Survey of Daiko Study in the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) 査読有り

MORITA Emi, HAMAJIMA Nobuyuki, HISHIDA Asahi, AOYAMA Kyoko, OKADA Rieko, KAWAI Sayo, TOMITA Koutaro, KURIKI Sayaka, TAMURA Takashi, NAITO Mariko, KONDO Takaaki, UEYAMA Jun, KIMATA Akiko, YAMAMOTO Kanami, HORI Yoko, HOSHINO Junko, HAMAMOTO Ritsuko, TSUKAMOTO Sanae, ONISHI Johji, HAGIKURA Shoichi, NAITO Hisao, HIBI Satoshi, ITO Yoshinori and WAKAI Kenji

Nagoya Journal of Medical Science 73 巻頁： 187-195 2011年8月

Effect of DDVP on urinary excretion levels of pyrethroid metabolite 3-phenoxybenzoic acid in rats 査読有り

HIROSAWA Naoko, UEYAMA Jun, KONDO Takaaki, KAMIJIMA Michihiro, TAKAGI Kenji, FUJINAKA Sanae, HIRATE Ayaka, HASEGAWA Takaaki, WAKUSAWA Shinya.

Toxicol Lett. 203 巻 ( 1 ) 頁： 28-32 2011年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

PubMed ID:21471973
Pyrethroid insecticide (PYR) is used worldwide in agriculture and for indoor extermination of harmful insects. Urinary PYR metabolites (e.g. 3-phenoxybenzoic acid, 3PBA) have been used as the most sensitive biomarker for environmental PYR exposure since the late 1990's. In this study, we examined the effect of organophosphorus insecticide (OP) dichlorvos (DDVP) on excretion levels of urinary cis-permethrin-derived 3PBA in rats. Concentration of urinary 3PBA and cis-permethrin in plasma were monitored using gas chromatography-mass spectrometry and high-performance liquid chromatography after cis-permethrin injection (20mg/kg) via the tail vein of rats pretreatmented intraperitoneally with DDVP (low dose, 0.3mg/kg; high dose, 1.5mg/kg). The amount of urinary 3PBA excretion over 48h after cis-permethrin administration in control was 21.5±5.1μg (mean±S.D.). In the low- and high-dose DDVP groups, the amounts of urinary 3PBA excretion were decreased to 81.1% (17.4±2.7μg) and 70.3% (15.1±2.6μg) of control, respectively. The plasma concentrations of cis-permethrin-derived 3-phenoxybenzyl alcohol (3PBAlc), which is a metabolite derived following hydrolysis of cis-permethrin, in high-dose DDVP group (0.18±0.01μg) were significantly lower than in control (0.23±0.03μg) 1h after cis-permethrin injection. Both in the control and high-dose DDVP group, no differences were observed in the excretion levels of urinary 3PBA after injection of 3PBAlc (25mg/kg, i.v). These results suggested that the effect of DDVP on the amount of urinary 3PBA excretion was caused by the DDVP-induced modification of the cis-permethrin metabolic pathway. In conclusion, the possible decrease in urinary excretion level of 3PBA due to co-exposure to OPs should be considered in the biological monitoring of PYR exposure.

Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. 査読有り

YAMADA Yuichiro, TSUBOI Koji, HATTORI Takuya, MURATE Takashi, OHTAKE Masafumi, FRUKAWA Mayuko, UEYAMA Jun, NISHIYAMA Akira, MUROHARA Toyoaki, NAGATA Kohzo.

Hypertens Res 34 巻 ( 7 ) 頁： 809-816 2011年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

PubMed ID21471973
Although thiazide diuretics are commonly used to supplement angiotensin receptor blockers for treatment of hypertension, the mechanism underlying the therapeutic effects of this drug combination remains unclear. We investigated the antihypertensive and cardioprotective effects of combination therapy with losartan (LOS) and hydrochlorothiazide (HCTZ), in comparison with those of either drug alone, in Dahl salt-sensitive hypertensive rats. Rats fed a high-salt diet from 6 weeks of age were treated with LOS, HCTZ, both drugs (COMB) and vehicle from 6 to 11 weeks. The salt-induced increase in systolic blood pressure was attenuated moderately by LOS and to a greater extent by HCTZ and COMB. Left ventricular (LV) hypertrophy and fibrosis, diastolic dysfunction, as well as angiotensin-converting enzyme and angiotensin II type 1A (AT(1A)) receptor gene expression were attenuated similarly by LOS and HCTZ and more so by COMB. LOS downregulated expression of the AT(1A) receptor gene, without affecting that of the AT(2) receptor gene, in the aorta. In contrast, neither HCTZ nor COMB affected aortic expression of the AT(1A) receptor gene, but both markedly upregulated that of the AT(2) receptor gene. The salt-induced decrease in the plasma concentration of nitric oxide metabolites was attenuated substantially by LOS and abolished by both HCTZ and COMB. In conclusion, the combination of LOS and HCTZ attenuated hypertension, as well as LV remodeling and diastolic dysfunction, more effectively than did LOS or HCTZ alone in rats with salt-sensitive hypertension. Modulation of the cardiac and vascular renin-angiotensin system may have contributed to these beneficial effects of the drug combination.

Association of UGT1A1 Gly71Arg with urine urobilinogen 査読有り

KATAOKA Ryuji, KIMATA Akiko, YAMAMOTO Kanami, HIROSAWA Naoko, UEYAMA Jun, KONDO Takaaki, OKADA Rieko, KAWAI Sayo, HISHIDA Asahi, NAITO Mariko, MORITA Emi, WAKITA Kenji, HAMAJIMA Nobuyuki

Nagoya Journal of Medical Science 73 巻 ( 1-2 ) 頁： 33-40 2011年4月

Involvement of sulfate conjugation and multidrug resistance-associated protein 2 (MRP2) in sex-related differences in the pharmacokinetics of garenoxacin in rats 査読有り

HAYASHI Tamon, ABE Fumie, KATO Miki, SAITO Hiroko, UEYAMA Jun, KONDO Yuya, IMAI Kuniyuki, KATOH Miki, NADAI Masayuki, HASEGAWA Takaaki

J Infect Chemother 17 巻 ( 1 ) 頁： 24-29 2011年2月

Beta-glucuronidase activity is a more sensitive biomarker than cholinesterase inhibition for organophosphorus insecticide exposure 査読有り

UEYAMA Jun, SATOH Tetsuo, KONDO Takaaki, TAKAGI Kenji, SHIBATA Eiji, GOTO Masahiro, KIMATA Akiko, SAITO Isao, HASEGAWA Takaaki, WAKUSAWA Shinya, KAMIJIMA Michihiro.

Toxicol Lett 193 巻 ( 1 ) 頁： 115-119 2010年12月

Endotoxin does not alter the pharmacokinetics of micafungin,but it impairs biliary excretion of micafungin via multidrugresistance-associated protein 2 (ABCC2/Mrp2) in rats 査読有り

NODA Takayuki, ABE Fumie, UEYAMA Jun, KATO Miki, KATOH Miki, NADAI Masayuki, SAITO Hiroko, HASEGAWA Takaaki

J Infect Chemother 2010年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

PubMed ID:20835743
Micafungin, a newly developed echinocandin-type antifungal agent, is widely used for the treatment of deep-seated fungal infections including those of Candida species and Aspergillus species. In the present study, the possible alterations in the pharmacokinetics and biliary excretion of micafungin were investigated in endotoxemic rats induced by Klebsiella pneumoniae endotoxin. Endotoxin (2 mg/kg) was injected intraperitoneally 24 h before an intravenous injection of micafungin (1 mg/kg). No significant differences in the plasma concentration-time curves and pharmacokinetic parameters of micafungin were observed between endotoxin-treated and endotoxin-untreated rats. When endotoxin-treated rats received a constant-rate infusion of micafungin, the biliary clearance of micafungin was significantly decreased, whereas the steady-state plasma concentration did not change. By protein immunoblot analysis, a significant decrease in the expression of hepatic multidrug resistance-associated protein 2 (ABCC2/Mrp2), which is an efflux protein for micafungin, was observed in endotoxin-treated rats. These results suggest that endotoxin-induced decrease in the hepatobiliary excretion of micafungin is caused, at least in part, by the reduction of Mrp2-mediated hepatobiliary transport ability. The present study may provide information suggesting that micafungin can be used for patients with endotoxemia without the need for dosage adjustment.

DOI： 10.1007/s10156-010-0118-9

　前のページ - 次のページ　

<上山 純>

論文 - 上山 純

<上山　純>

論文 - 上山　純